Advertisement
Canada markets close in 3 hours 14 minutes
  • S&P/TSX

    22,321.36
    +61.89 (+0.28%)
     
  • S&P 500

    5,193.48
    +12.74 (+0.25%)
     
  • DOW

    38,881.32
    +29.05 (+0.07%)
     
  • CAD/USD

    0.7294
    -0.0027 (-0.37%)
     
  • CRUDE OIL

    78.71
    +0.23 (+0.29%)
     
  • Bitcoin CAD

    87,149.72
    +204.45 (+0.24%)
     
  • CMC Crypto 200

    1,319.36
    -45.76 (-3.35%)
     
  • GOLD FUTURES

    2,323.00
    -8.20 (-0.35%)
     
  • RUSSELL 2000

    2,077.26
    +16.58 (+0.80%)
     
  • 10-Yr Bond

    4.4370
    -0.0520 (-1.16%)
     
  • NASDAQ

    16,381.45
    +32.20 (+0.20%)
     
  • VOLATILITY

    13.45
    -0.04 (-0.30%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6768
    -0.0024 (-0.35%)
     

Gilead Sciences May Witness Significant Drop in Revenues in 2018

Gilead Sciences May Witness Significant Drop in Revenues in 2018

Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...